All Data
A partner for the pharma and biotech industries to improve patient outcomes & quality of life
Lead Product(s): Clascoterone
Therapeutic Area: Dermatology Product Name: Winlevi
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Cassiopea
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 04, 2020
Details:
Albany Molecular Research has been named as the exclusive supplier of the active pharmaceutical ingredient (API) in Cassiopea SpA’s (SIX: SKIN) recently approved acne treatment, Winlevi® (clascoterone) cream 1%.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Azeloglycine
Therapeutic Area: Dermatology Product Name: Iwostin
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Perrigo Company plc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 02, 2020
Details:
Perrigo has completed the acquisition of three Eastern European OTC skincare and hair loss treatment brands, Emolium®, Iwostin® and Loxon® from Sanofi. The acquisition has opened door for Perrigo's transformation to a consumer-focused, global self-care company.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Azeloglycine
Therapeutic Area: Dermatology Product Name: Iwostin
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Perrigo Company plc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 11, 2020
Details:
Perrigo will acquire three Eastern European OTC skincare and hair loss treatment brands (Emolium®, Iwostin® and Loxon®) from Sanofi.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dupilumab
Therapeutic Area: Dermatology Product Name: Dupixent
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2020
Details:
Recommendation was supported by multiple clinical trials that demonstrated superiority of Dupixent® over placebo in improving disease extent and severity, skin clearance and itch intensity, as well as health-related quality of life.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lidocaine,Tetracaine
Therapeutic Area: Dermatology Product Name: Pliaglis
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Juyou Biotechnology
Deal Size: $2.9 million Upfront Cash: $0.1 million
Deal Type: Licensing Agreement November 05, 2020
Details:
Under the terms of the agreement, Juyou will look after overall clinical development and regulatory filings for Pliaglis with the National Medical Products Administration (the "NMPA", formerly the China State Food and Drug Administration.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Baricitinib
Therapeutic Area: Dermatology Product Name: Olumiant
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Incyte Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2020
Details:
New data for baricitinib for the treatment of moderate to severe atopic dermatitis showed that baricitinib 4-mg and 2-mg dose groups were able to maintain clear or almost clear skin response rates through the 68-week treatment period.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ixekizumab
Therapeutic Area: Dermatology Product Name: Taltz
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
Taltz demonstrated sustained efficacy in adult psoriasis patients with baseline scalp, nail and palmoplantar (skin on the palms of the hands and soles of the feet) involvement with the following results at five years.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dupilumab
Therapeutic Area: Dermatology Product Name: Dupixent
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
Presentations include data from open-label extension trials evaluating laboratory assessments in adults treated with Dupixent for up to three years and adolescents (aged 12 to 17 years) treated up to one year.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Calcipotriol,Betamethasone Dipropionate
Therapeutic Area: Dermatology Product Name: Enstilar
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2020
Details:
U.S. Prescribing Information (USPI) updated to include PSO-LONG clinical trial data concerning long-term use (52 weeks) of twice-weekly topical treatment with Enstilar® (calcipotriene and betamethasone dipropionate) Foam in adults with plaque psoriasis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dupilumab
Therapeutic Area: Dermatology Product Name: Dupixent
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2020
Details:
Recommendation based on pivotal trial that showed Dupixent plus topical corticosteroids (TCS) significantly improved measures of overall disease severity, skin clearance, itch and health-related quality of life, compared to TCS alone .
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
